Biogen (BIIB) Gains from Investment Securities (2024 - 2026)
Biogen (BIIB) posted quarterly Gains from Investment Securities of $2.5 million for Q2 2026, down 81.06% year-over-year from $13.2 million in Q2 2025, and down 87.8% quarter-over-quarter from $20.5 million in Q1 2026.
Biogen (BIIB) Gains from Investment Securities (2024 - 2026) Analysis & Trends
Biogen's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $2.5 million for Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Jun 30, 2026 | 2.50 Mn |
| Mar 31, 2026 | 20.50 Mn |
| Mar 31, 2026 | 20.50 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 13.20 Mn |
| Jun 30, 2025 | 13.20 Mn |
| Mar 31, 2025 | 9.60 Mn |
| Mar 31, 2025 | 9.60 Mn |
| Sep 30, 2024 | 23.80 Mn |
| Sep 30, 2024 | 23.80 Mn |